The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: A nested case-control study in the California Teachers Study cohort

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Lee, Eunjung ^a   Schumacher, Fredrick ^a   Lewinger, Juan Pablo ^a   Neuhausen, Susan L ^b   Anton Culver, Hoda ^c   Horn Ross, Pamela L ^d   Henderson, Katherine D ^b   Ziogas, Argyrios ^c   Van Den Berg, David ^a   Bernstein, Leslie ^b   Ursin, Giske ^a,e,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^e UNIVERSITY OF OSLO   (Norway)

^f CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; ORGANIC ANION TRANSPORTER 2; ESTROGEN; ORGANIC ANION TRANSPORTER; PROGESTERONE; SLCO1B1 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HORMONAL THERAPY; HORMONE METABOLISM; HUMAN; LIVER CELL; MAJOR CLINICAL STUDY; MENOPAUSE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; AGED; BREAST TUMOR; COHORT ANALYSIS; ESTROGEN THERAPY; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MENOPAUSE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGESTERONE; RISK FACTORS;

EID: 84860389248     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2859     Document Type: Article

References (68)

1. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002, 360:187-195. Collaborative Group on Hormonal Factors in Breast Cancer.
2. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993, 15:36-47.
3. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616.
4. Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst 2005, 97:595-602. 10.1093/jnci/dji099, 15840882.
5. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98:1406-1415. 10.1093/jnci/djj376, 17018787.
6. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997, 350:1047-1059. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.
7. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000, 92:328-332. 10.1093/jnci/92.4.328, 10675382.
8. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000, 283:485-491. 10.1001/jama.283.4.485, 10659874.
9. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003, 97:1387-1392. 10.1002/cncr.11205, 12627501.
10. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005, 3:CD004143. 16034922, 16034922.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397.
12. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998, 19:1-27. 10.1093/carcin/19.1.1, 9472688.
13. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burtt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Lenner P, Lund E, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007, 67:1893-1897. 10.1158/0008-5472.CAN-06-4123, 17325027.
14. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004, 96:936-945. 10.1093/jnci/djh167, 15199113.
15. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13:94-101. 10.1158/1055-9965.EPI-03-0026, 14744739.
16. Beckmann L, Husing A, Setiawan VW, Amiano P, Clavel-Chapelon F, Chanock SJ, Cox DG, Diver R, Dossus L, Feigelson HS, Haiman C, Hallmans G, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw K, Kolonel LN, Kraft P, Lund E, Le Marchand L, Peeters PH, Riboli E, Stram D, Thomas G, Thun MJ, Tumino R, Trichopoulos D, Vogel U, Willett WC, et al. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab 2011, 96:E360-367. 10.1210/jc.2010-0912, 21177793.
17. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999, 8:843-854.
18. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:215-216.
19. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999, 59:1015-1020.
20. Becchis M, Frairia R, Ferrera P, Fazzari A, Ondei S, Alfarano A, Coluccia C, Biglia N, Sismondi P, Fortunati N. The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. Breast Cancer Res Treat 1999, 54:101-107. 10.1023/A:1006100929670, 10424400.
21. Forsti A, Jin Q, Grzybowska E, Soderberg M, Zientek H, Sieminska M, Rogozinska-Szczepka J, Chmielik E, Utracka-Hutka B, Hemminki K. Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer. Carcinogenesis 2002, 23:1315-1320. 10.1093/carcin/23.8.1315, 12151349.
22. Low YL, Dunning AM, Dowsett M, Luben RN, Khaw KT, Wareham NJ, Bingham SA. Implications of gene-environment interaction in studies of gene variants in breast cancer: an example of dietary isoflavones and the D356N polymorphism in the sex hormone-binding globulin gene. Cancer Res 2006, 66:8980-8983. 10.1158/0008-5472.CAN-06-2432, 16982738.
23. Masson LF, Sharp L, Cotton SC, Little J. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. Am J Epidemiol 2005, 161:901-915. 10.1093/aje/kwi121, 15870154.
24. Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, Hirschhorn J, Henderson BE. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003, 12:2679-2692. 10.1093/hmg/ddg294, 12944421.
25. Setiawan VW, Cheng I, Stram DO, Giorgi E, Pike MC, Van Den Berg D, Pooler L, Burtt NP, Le Marchand L, Altshuler D, Hirschhorn J, Henderson BE, Haiman CA. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer. Cancer Res 2006, 66:12019-12025. 10.1158/0008-5472.CAN-06-1101, 17178901.
26. Zheng W, Gao YT, Shu XO, Wen W, Cai Q, Dai Q, Smith JR. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004, 13:709-714.
27. Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000, 462:323-333. 10.1016/S1383-5742(00)00018-1, 10767642.
28. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA. Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 2007, 3:e42. 10.1371/journal.pgen.0030042, 1828694, 17367212.
29. Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, Henderson BE, Albanes D, Altshuler D, Berglund G, Berrino F, Bingham S, Buring JE, Burtt NP, Calle EE, Chanock SJ, Clavel-Chapelon F, Colditz G, Diver WR, Freedman ML, Haiman CA, Hankinson SE, Hayes RB, Hirschhorn JN, Hunter D, Kolonel LN, Kraft P, LeMarchand L, Linseisen J, Modi W, Navarro C, et al. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res 2006, 66:2468-2475. 10.1158/0008-5472.CAN-05-3574, 16489054.
30. Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanche H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, Delancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Husing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet 2010, 19:3873-3884. 10.1093/hmg/ddq291, 20634197.
31. Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 2010, 19:2366-2378. 10.1158/1055-9965.EPI-10-0162, 20699377.
32. Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West D, Wright W, Ziogas A, Ross RK. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002, 13:625-635. 10.1023/A:1019552126105, 12296510.
33. California Teachers Study homepage. , http://calteachersstudy.org/
34. Kwong S, Perkin C, Morris C, Cohen R, Allen M, Wright W. Cancer in California: 1988-1999 2001, Sacramento, CA: California Department of Health Services, Cancer Surveillance Section.
35. Li J, Eriksson L, Humphreys K, Czene K, Liu J, Tamimi RM, Lindström S, Hunter DJ, Vachon CM, Couch FJ, Scott CG, Lagiou P, Hall P. Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. Breast Cancer Res 2010, 12:R19. 10.1186/bcr2488, 2879563, 20214802.
36. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004, 25:947-970. 10.1210/er.2003-0030, 15583024.
37. Edlund CK, Lee WH, Li D, Van Den Berg DJ, Conti DV. Snagger: a user-friendly program for incorporating additional information for tagSNP selection. BMC Bioinformatics 2008, 9:174. 10.1186/1471-2105-9-174, 2375134, 18371222.
38. International HapMap Project homepage. , http://hapmap.ncbi.nlm.nih.gov
39. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003, 55:27-36. 10.1159/000071807, 12890923.
40. Li Y, Abecasis GR. Mach 1.0: Rapid Haplotype Reconstruction and Missing Genotype Inference. Am J Hum Genet 2006, S79:2290.
41. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2007, 16:2237-2246. 10.1158/1055-9965.EPI-07-0589, 18006912.
42. Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y, Sun L. The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects. Breast Cancer Res Treat 2011, 125:215-219. 10.1007/s10549-010-0953-5, 20505990.
43. Wang Z, Fu Y, Tang C, Lu S, Chu WM. SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls. Breast Cancer Res Treat 2010, 122:193-198. 10.1007/s10549-009-0648-y, 19949855.
44. Economopoulos KP, Sergentanis TN. Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 122:545-551. 10.1007/s10549-009-0728-z, 20054638.
45. Yao L, Fang F, Wu Q, Zhong Y, Yu L. No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40,303 subjects. Breast Cancer Res Treat 2010, 122:237-242. 10.1007/s10549-009-0689-2, 20033481.
46. Mao C, Wang XW, Qiu LX, Liao RY, Ding H, Chen Q. Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls. Breast Cancer Res Treat 2010, 121:719-725. 10.1007/s10549-009-0650-4, 20464630.
47. Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O, Andrulis IL, Blomqvist C, Nevanlinna H, Ozcelik H. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 2008, 8:6. 10.1186/1471-2407-8-6, 2254632, 18194538.
48. Ding H, Fu Y, Chen W, Wang Z. COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case-control studies. Breast Cancer Res Treat 2010, 123:265-270. 10.1007/s10549-010-0759-5, 20130981.
49. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR. Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005, 14:1998-2003. 10.1158/1055-9965.EPI-05-0076, 16103451.
50. Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A, Berlin M, Schinnar R, Berlin JA, Strom BL. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev 2007, 16:444-450. 10.1158/1055-9965.EPI-06-0800, 17372239.
51. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 2010, 119:463-474. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.
52. Reding KW, Weiss NS, Chen C, Li CI, Carlson CS, Wilkerson HW, Farin FM, Thummel KE, Daling JR, Malone KE. Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009, 18:1461-1467. 10.1158/1055-9965.EPI-08-0917, 2764317, 19383894.
53. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, Han W, Kim JS, Shin SG, Jang IJ, Yoo KY, Hirvonen A, Kang D. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1090-1095. 10.1158/1055-9965.EPI-04-0688, 15894657.
54. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Bruning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res 2008, 68:5997-6005. 10.1158/0008-5472.CAN-08-0043, 2518124, 18632656.
55. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 2008, 108:137-149. 10.1007/s10549-007-9586-8, 17588204.
56. Reding KW, Li CI, Weiss NS, Chen C, Carlson CS, Duggan D, Thummel KE, Daling JR, Malone KE. Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk. Am J Epidemiol 2009, 170:1241-1249. 10.1093/aje/kwp298, 2781763, 19846565.
57. Gaudet MM, Chanock S, Lissowska J, Berndt SI, Peplonska B, Brinton LA, Welch R, Yeager M, Bardin-Mikolajczak A, Garcia-Closas M. Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk. Cancer Res 2006, 66:9781-9785. 10.1158/0008-5472.CAN-06-1294, 17018638.
58. Jansson A, Carlsson J, Olsson A, Storm P, Margolin S, Gunnarsson C, Stenmark-Askmalm M, Lindblom A, Persson B, Stal O. A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer. Breast Cancer Res Treat 2007, 106:57-64. 10.1007/s10549-006-9477-4, 17260097.
59. Low YL, Li Y, Humphreys K, Thalamuthu A, Darabi H, Wedren S, Bonnard C, Czene K, Iles MM, Heikkinen T, Aittomaki K, Blomqvist C, Nevanlinna H, Hall P, Liu ET, Liu J. Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLoS Genet 2010, 6:e1001012. 10.1371/journal.pgen.1001012, 2895650, 20617168.
60. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009, 158:693-705. 10.1111/j.1476-5381.2009.00430.x, 2765590, 19785645.
61. van der Deure WM, Friesema EC, de Jong FJ, de Rijke YB, de Jong FH, Uitterlinden AG, Breteler MM, Peeters RP, Visser TJ. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology 2008, 149:4695-4701. 10.1210/en.2008-0169, 18499754.
62. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 2001, 18:1262-1269. 10.1023/A:1013077609227, 11683238.
63. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 2006, 90:5-22.
64. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility 2005, Philadelphia: Lippincott Williams & Wilkins, 7.
65. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001, 276:35669-35675. 10.1074/jbc.M103792200, 11477075.
66. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002, 302:804-813. 10.1124/jpet.302.2.804, 12130747.
67. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874. 10.1038/ng2075, 17529973.
68. Conneely KN, Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 2007, 81:1158-1168. 10.1086/522036, 17966093.